Seeking a Sustainable Business Developing on N-of-1 Therapies

The ability to pinpoint the underlying genetic causes of diseases and rapidly generate genetic medicines to address them has created the potential for the development of individualized therapies to treat patients with ultra-rare conditions. EveryOne Medicines is seeking to industrialize this process and scale the development of N-of-1 therapies. We spoke to Irina Antonijevic, chief medical officer of Everyone Medicines, about the company’s business model for pursuing N-of-1 therapies for people with rare diseases, how it works, and whether it can be sustainable absent a mechanism for reimbursement.